Jury Still Out on Cardiovascular Safety of Testosterone Jury Still Out on Cardiovascular Safety of Testosterone

A meta-analysis may provide some reassurance of the short-term cardiovascular safety of testosterone therapy for male hypogonadism until definitive 5-year TRAVERSE trial findings are available, expected in late 2022.Medscape Medical News

Source: Medscape Cardiology Headlines - June 9, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news